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Infection of inbred mouse strains with Leishmania major causes local infectionwith
subsequent resolution and establishment of immunity in genetically resistant mice,
but progressive, disseminated fatal disease in genetically susceptible mice. Healing
in resistant strains, such as C57BL/6, is associated with thecapacity oflymphocytes
to generateIFN-y in response to Leishmania antigens in vitro (1) and the appearance
ofIFN-y mRNA in lymphoid tissues in vivo (2) . IFN-y has been identified as the
major macrophage-activating factor produced by stimulated T cells (3-5), and is
capable of activating macrophages to kill the obligate intracellular amastigote form
of the parasite (6-8) .
Susceptible BALB/c mice can be immunologically manipulated before infection,
e.g ., by sublethal irradiation (9) or transient depletion ofCD4+T cells with the anti-
CD4mAbGK1.5 (GK1.5-BALB/c ; 1, 10), such that these animals contain infection
and establish protective immunity against reinfection . The control of infection in
these mice has also been correlated with production ofIFN-y by T cells in vivo and
in vitro (1, 2) . Untreated BALB/c mice, however, do not generate significant IFN-y,
despite the demonstrable expansion of the CD4+ T cell population during progres-
sive infection (2, 11). In contrast to the healing mice, these animals have mRNA
for IL-4 in lymphoid tissues in vivo together with elevated levels ofserum IgE (2) .
These data suggest that healing or fatally infected BALB/c mice expand distinct
CD4 + T cell subsets that correlate with control or progression of disease . These in
vivo cells would be correlates of the Thl andTh2 cells previously distinguished and
defined at the clonal level in vitro (12, 13) .
Based on these observations, we administered an IL-4-specific neutralizingmAb
in orderto interfere with expansion andfunction ofTh2 cell populations in infected
BALB/c mice . In preliminary experiments, such therapy clearlyattenuated the course
ofearly disease (2). In experiments reported here, anti-IL-4 therapy initiated at the
time ofinfection attenuated disease in 100% of susceptibleBALB/c mice andresulted
in complete resolution ofdisease in85% ofmice with theestablishment ofprotective
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immunity. Further, cure was independent ofIFN-y, asjudged by the failureofcoad-
ministration ofneutralizing anti-IFN-y mAbto altertheoutcome of anti-IL-4therapy .
This was in contrast to resistant C57BL/6 or GK1.5-BALB/c mice, both of which
developed progressive infection when treated with anti-IFN-y mAb.
Materials and Methods
Mice.
￿
Female BALB/c and C57BL/6mice, 6-8wk old, were purchasedfrom TheJackson
Laboratory, Bar Harbor,ME . Female athymic nude BALB/c (nu/nu) mice, 6-8 wk old, were
purchased from Harlan Sprague Dawley, Inc., Indianapolis, IN, and housed in the specific
pathogen-free animal care facility at U.C.S.F. Medical Center.
Parasites.
￿
L. major(World Health Organization strain WHOM/IR/-/173) wascultured as
promastigotes inM199 (CellCulture Facility,U.C.S.F. Medica l Center) containing 30 1 7o FCS
(Gemini Bio-Products, Calabasas, CA) as described (14, 15) . Metacyclic stage promastigotes
were harvested from stationary phase cultures by centrifugation and washed in HBSS (Cell
Culture Facility, U.C.S.F. Medical Center) before use .
mAbs.
￿
mAbs included GK1.5 (rat IgG2b), which recognizes themurineCD4 antigen (16),
53-6.72 (rat IgG2a), which recognizes themurine CD8antigen (17), R4 6A2 (rat IgGl), which
neutralizes murine IFN-'y (18), and 11B11 (rat IgGI), which neutralizes murine IL-4 (19) .
mAbs were prepared from rat/mouseheterohybridomas grown as ascites in pristane-primed
BALB/c nu/numice. Preparations were precipated in 45%ammonium sulfate, dialyzed against
PBS, pH 7.2, and quantitated for protein before use (20) .
IFN-y .
￿
Purified murine rIFN-y (lot no. 2271-54-F1 ; sp act, 5 x 106 antiviral U/mg; en-
dotoxin, 0.032 E.U./mg), provided as a 1 mg/ml solution in sterile buffered saline (Genen-
tech, Inc., South San Francisco, CA), was diluted to 100 kg/ml in sterile normal saline, ali-
quoted, and stored atVC before use. Beginningwith the dayof infection, designated BALB/c
mice received 20 hg rIFN-y intraperitoneally every other day for 6 wk .
Infection of Mice with mAbs.
￿
Selected BALB/c mice were injected intraperitoneally with
1.0 mg purified GK1 .5 in 250 p,l PBS 24 h before infection, as described (1, 10) . Beginning
on the dayof infection, designated mice received 0.5 mg purified 11BIl or R4 6A2, or both,
intraperitoneally once per week for 6 wk .
Infection ofMice.
￿
Mice were infected in the hind footpads with 4 x 10 6 metacyclic stage
L. major promastigotes, as described (1, 21) . Footpad swelling was determined weekly using
a metric caliper. At the times designated, sera were collected and the animals were killed .
The tissue from the dorsal portion of the footpads was removed intact and frozen in OCT
compound (Miles Laboratories Inc., Naperville, IL) . After thin sectioning on a cryostat (In-
ternational Equipment Co ., Needham Heights, MA), the largest transverse diameter was
prepared for histologic examination after staining with modified Wright/Geimsa (Dif Quik ;
American Scientific Products, McGawPark, IL) . The spleens anddraining (popliteal) lymph
nodes were used for the isolation of mRNA (see below) .
Adoptive Transfer of Cellular Immunity.
￿
Spleen and popliteal lymph node cells were isolated
from anti-IL-4-healed L . major-infected BALB/c mice at 12-15 wk after infection . The cells
were pooled and divided into three aliquots . Twowere depleted ofCD4* cells orCD8* cells
by incubation with 10 14g/ml anti-CD4 mAb or 10 pg/ml anti-CD8 mAb, respectively, fol-
lowed by incubation with 1 :10 diluted complement (Rabbit LowToxM; Accurate Chemical
& Scientific Corp ., Westbury, NY). Twocycles of depletion were performed with the respec-
tive antibodies . Depletionwasconfirmedby flow cytometry. Thethird group ofcells received
no treatment. Groups of five recipient BALB/c mice were irradiated with 200 rad (22) before
intravenous administration of 10' cells from one of the three cell preparations . Control
BALB/c mice were similarly irradiated but received 10' naive BALB/c spleen cells. Addi-
tional groups included untreatedmice and irradiated mice that didnot receive any cell transfer.
All mice were infected 24 h after cell transfer. Disease progression was assessed by footpad
swelling and ulceration .
Northern Blot Analyses.
￿
Harvested tissues were homogenizedin 6M guanidine hydrochlo-
ride and isolated by the method of Chirgwin et al . (23). Poly(A)* RNA was subsequently
purified usingoligo-dT affinity chromatography (24), subjected to electrophoresis in 67o form-aldehyde/1% agarose gel (25), and transferred to nylon membranes by capillary blotting (Amer-
sham Corp ., Arlington Heights, IL) (26) . The membranes were exposed to short-wave UV
light for 30 s to fix the RNA to the nylon matrix, and treated at 42°C for 4 h with prehybridiza-
tion solution containing 10% dextran before incubation with 12P-labeled nucleic acid probe.
The probes used were IL-4 cDNA subcloned into pSP65 (2), and the 550-bp Eco RI/Eco
RV fragment of murine IFN-y (Dr. P W. Gray, Genentech, Inc .) subcloned into PSP72
(Promega Biotec, Madison, WI) . IFN-y and IL-4 antisense probes were generated using
12P-CTP (800 Ci/mmole ; New England Nuclear, Boston, MA) and SP6 RNA polymerase
(Promega Biotec) as described (2) . Membranes were hybridized with antisense RNA probes
at 65°C overnight, and washed in 0.1% SDS, 0 .1 x SSC (0.015 M NaCl, 0.0015 M sodium
citrate buffer, pH 7.0) at 65°C . Membranes were hybridized with nick-translated cDNA probe
at 42°C overnight and washed in 0.1% SDS, 0 .1 x SSC at 55°C . Washed membranes were
exposed to X-ray film as previously described (2) .
Serum IgEDeterminations.
￿
Sera isolated before death were quantitated for IgE using a sand-
wichELISA with monoclonal anti-e (EM-95) as the primary antibody and biotinylated poly-
clonal rabbit-anti-4E as the secondary antibody, as described (27) .
Results
Effect ofExogenous rIFN-y in Infected BALBIc Mice.
￿
The low levels of IFN-'y pro-
duced during progressive L . major infection in susceptibleBALB/c mice, in contrast
to the readily detectable levels produced by resistantC57BL/6 mice (1, 2), suggested
that parenterally administeredrIFN-y might favorably influence theoutcome of in-
fection in the BALB/c mice . Based on preliminary experiments, a dose of IFN-y
that was twofold below that resulting in toxicity to infected mice was used . This dose,
20 ug every 48 h, was twice that used to cure otherwise fatal murine Toxoplasma gondii
(28, 29) or Trypanosoma cruzi (30) infection . InfectedBALB/c mice receiving rIFN-y
demonstrated a slight delay in footpad swelling (Fig. 1), but ulceration and histo-
logic evidence of extensive parasitization occurred in all animals (Fig. 2 C) . At 5
wk post-infection, however, treated mice had significant diminution in serum IgE
levels compared with control-infected mice (Fig . 3), indicating in vivo efficacy of
the exogenous IFN-'Y (27).
Effect of In Vivo Neutralization ofIL-4 on the Course of Leishmaniasis in BALBIc Mice.
BALB/c mice that received six weekly injections of anti-IL-4 mAb (11B11) exhibited
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FIGURE 1 .
￿
Effect ofrIFN-y or
anti-IL-4 treatment on the
progression ofL. major infection
in BALB/c mice . Footpad mea-
surements represent the mean
t SEM from 48 mice after no
treatment (O) or anti-IL-4 treat-
ment (" ), and themean t SEM
from five mice after rIFN-y
treatment (A) .118
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FIGURE 2 .
￿
Effect of rIFN-y or
anti-IL-4 treatmenton the pro-
gression ofL. major infection in
BALB/c mice . Tissue sections
were prepared from the footpads
of8-wk-infected untreated (A),
anti-IL-4-treated (B),.'and rIFN-
,y- treated (C) BALB/c mice and
represent the largest transverse
diameter from the dorsal sur-
face of the infected footpads
(x 750) .
significant attenuation ofdisease ascompared withmatcheduntreated animals (Fig .
1) . Footpadswelling was markedly decreased and beganto resolve after 6 wk, whereas
footpads ofthe control animals progressed to ulceration and necrosis . Although dis-
ease did progress, albeit more slowly, in some of the treated mice, 85% were com-8 .00
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pletely healed by 8wk. These data represent thecompiled resultsfrom 48 mice treated
with anti-IL-4 . Histologic analyses of the footpads from the treated BALB/c mice
confirmed that the resolution of swelling was associated with the disappearance of
parasites(Fig . 2,A and B) . In additional experiments, the coadministration of rIFN-,y
(20lzgevery48 h) with anti-IL-4therapydid not augmentthebeneficial effect achieved
by anti-IL-4 alone (data not shown) . Serum IgE levels were suppressed by >90%
in anti-IL-4-treated mice, as compared with control-infected BALB/c mice (Fig . 3) .
In contrast, BALB/c mice that received weekly injections of either nonimmune rat
sera or isotype-matchedR4 6A2 anti-IFN--y (rat IgGI)developeddiseaseandelevated
serum IgE levels indistinguishable from those in untreated infected BALB/c mice
(data not shown) .
Anti-IL-4 Effect Is Dependent on TCells.
￿
When healed, anti-IL-4-treated BALB/c
mice were rechallenged with viable promastigotes, they remained immune to rein-
fection (datanot shown) . Pooled spleenandlymph node cellsfrom anti-IL-4-treated
BALB/c mice that had resolved the primary infection were transferred into irradi-
ated BALB/c recipients before challenge with L. major promastigotes. These mice,
but not mice receiving naive BALB/c spleen cells, displayed substantial protection
against the parasite, as assessed both by footpad swelling and ulceration (Fig . 4) .
FIGURE 4.
￿
Adoptive transfer ofanti-IL-
4-induced immunity . Footpad measure-
ments from untreated L . major-infected
BALB/c mice (A) and L . major-infected
200-rad irradiated BALB/c mice that had
been injected with 107 naive BALB/c
spleen cells (A), 107 pooled lymphoid
cellsfrom anti-IL-4-healed BALB/c (0),
107 C134-depleted pooled lymphoid cells
from anti-IL-4-healed BALB/c (O), or
107 CD8-depleted pooled lymphoid cells
fromanti-IL-4-healed BALB/c (") . Values
represent the mean t SEM from five
,---~
￿
mice. Percentage of footpads ulcerated at
6
￿
7
￿
6 wk is indicated .
FIGURE 3 .
￿
Effect ofanti-IL-4,
rIFN- .y , or anti-IFN-,y on the
production of serum IgE after
L . major infection . Values rep-
resent the mean t SEM from
five mice .120
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Prior irradiation at these doses (in contrast to higher doses [9]) had no effect on
the subsequent course of leishmaniasis as compared with nonirradiated controls.
Treatment of the pooled cells with either anti-CD4 or anti-CD8 plus complement
significantly abrogatedthe capacity of thetransferred cells to preventfootpadswelling
and completely reversed the prevention of ulceration. To establish further the re-
quirement forT cellsin the efficacy of anti-IL-4, athymic BALB/c nu/nu mice, which
are unable to controlleishmaniasis in the absence of Tcell reconstitution (31), were
infected with L. major. Such mice showed no alteration of disease progression in re-
sponse to weekly anti-IL-4 injections (Fig. 5). Although footpad swelling wasdelayed
in nude mice as compared with normal infected BALB/c mice, as previously reported
(31), histologic analysis of the infected footpads and lymphnodes at week 6 revealed
extensive parasitization of macrophages from both control and anti-IL-4-treated nude
mice (data not shown).
Effect ofAnti-IL-4 on IFN-yandIL-4 mRNA.
￿
Prior studies have documented the
correlation between the presence of IFN-y mRNA and the capacity to heal L. major
infection (1, 2). To assess the possible role of IFN-y in the therapeutic response of
anti-IL-4-treated mice, mRNA extracted from the spleens and lymph nodes of in-
fected mice was examined for IFN-y-specific transcripts. Although Northern blot
analysis of splenic IFN-y mRNA from the anti-IL-4-healed BALB/c mice revealed
no differences as compared with untreated mice (Fig. 6, lanes A and B), message
levels in the draining lymph nodes were approximately fourfold enhanced (Fig. 6,
lanes C and D). Analysis of IL-4 mRNA in the same tissues similarly revealed no
change in splenic message levels accompanying anti-IL-4 treatment, but a reciprocal
fourfold decrease in specific mRNA in lymph node mRNA.
IFN-y Does not Mediate Healing Induced by Anti-IL-4.
￿
To investigate further the
mechanism of healing, in vivo neutralization of IFN-y with anti-IFN-y mAb, R4
6A2, was used to assess therole ofthis cytokine in anti-IL-4-treatedBALB/c, C57BL/6,
and GK1.5-BALB/c mice.
L. major-infected BALB/c mice receivingboth anti-IL-4 and anti-IFN-1' antibodies
containedtheinfection, as well as those receivinganti-IL-4alone (Fig. 7A). In marked
contrast, infected C57BL/6 mice receiving anti-IFN-y demonstrated progressive
swelling of the footpads with ulceration by week 5 (Fig. 7 B). A correlation between
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Effect ofanti-IL-4 treatmenton
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FIGURE 6 .
￿
Effect of anti-IL-4 treatment on cytokine mRNA
production during leishmaniasis. Poly(A)' RNA (10 pg)was iso-
lated from the spleens of untreated or anti-IL-4-treated BALB/c
mice (lanesA and B, respectively) or the popliteal lymph nodes
of untreated or anti-IL-4-treated BALB/c mice (lanes C and D,
respectively) 6wk after infection with L. major. Northern hybrid-
izations were performed using IL-4- and IFN-,y-specific probes .
FIGURE 7 .
￿
Effect ofanti-IFN-'y on the pro-
gression ofL . major infection . (A) Untreated
BALB/c mice (O); anti-IL-4-treated (A) ; and
anti-IL-4 + anti-IFN--y-treated (A)BALB/c
mice. Footpad measurements represent the
mean t SEM from five mice. (B) Untreated
BALB/c mice (O) ; C57BL/6 untreated (A) ;
and anti-IFN-'y-treated (A) mice . Footpad
measurements represent the mean t SEM
from four mice . (C) UntreatedBALB/c mice
(O) ; GK1.5-BALB/c untreated (A) ; and anti-
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footpad swelling and the presence of numerous parasites was confirmed by histo-
logic examinationofthe footpads in which amastigote-parasitized macrophageswere
readilydetectable (Fig. 8 B). Untreated C57BL/6 mice responded to infection with
footpad swelling through the first 5-6 wk, followed by resolution without ulceration
(Fig. 7 B). Resolution ofdisease wasconfirmed by histologic examination(Fig. 8 A).
Similar results were seen when GK1.5-BALB/c mice were treated with anti-IFN--y.
Neutralization of IFN-y resulted in progressive infection as assessed both by size
of the local lesions and increasing numbers of amastigote-infected macrophages in
the footpads (Figs. 7 Cand 8, Cand D, respectively). In both C57BL/6 and GK1.5-
BALB/c mice, neutralization of IFN-y resulted in significant increasesin serumIgE
levels as compared with untreated infected mice (Fig. 3).
Discussion
These studies demonstrate the profound effect of neutralization of IL-4 on the
course ofotherwise fatal infection by L. major in susceptible BALB/c mice. All treated
mice had attenuated disease, and 85% were cured. The efficacy of anti-IL-4 treat-
ment required the presence of T cells, and anti-IL-4-induced protection could be
adoptively transferred in a manner dependent on both CD4+ and CD8+ cells. Sur-
prisingly, there was no evidence that cure was mediated by the generation of IFN-'r,
despite the demonstration that this cytokine was critical for healing in C57BL/6 or
GK1.5-BALB/c mice. Further, treatmentwith rIFN-y alone was insufficient to affect
the course of disease in infected BALB/c mice, a finding consistent with at leasttwo
mechanisms for establishing control of leishmaniasis.
The effect ofanti-IL-4 therapywas established by measurement of footpad thick-
ness, histologic examinations demonstrating absence of parasites, and resistance of
mice to rechallenge with promastigotes 12 wk subsequent to the initial infection.
Neither control rat sera nor an isotype-matched mAb had any effect on the course
of disease, suggesting that neutralization ofIL-4 is required foractivity. The finding
that anti-IL-4 therapy abrogated the rise in serum IgE seen in untreated, infected
BALB/c mice further documents the neutralization of IL-4 in vivo (32-34). Treat-
ment of infected nu/nu BALB/c mice with anti-IL-4 had no effect on the course of
disease, indicating that T cells are required. Thelatter experiment furtherexcluded
the possibility of direct antileishmanial activity by the anti-IL-4 mAb.
Because IL-4 has been proposed as a requisite growth factor for Th2 cells (13,
35), ourinitial assumption was that anti-IL-4 therapy was effective due to a selective
blockade of the expansion of Leishmania antigen-specific Th2 cells. The decrease in
IL-4 mRNA and reciprocal increase in IFN-y mRNA that occurred in the lymph
node cells draining the lesion were consistent with a proportionately greater expan-
sion ofThl cellsin response to inhibition ofTh2 cell division by anti-IL-4. However,
several observations suggest that this may not be the only mechanism. rIFN-y has
also been shown to effectively blockTh2 cell proliferation in vitro (36), but despite
administration of rIFN-y at doses shown to effectively ameliorate fatal infection by
T . gondii (29, 30)or by T . cruzi (31), mice infected with L. majordeveloped progressive
infection. Suppression ofserumIgE, comparable with that seen in anti-IL-4-treated
mice, demonstrated that the administered rIFN-y induced systemic effects up to
5 wk after infection. As macrophagesare theonly host cell parasitized by Leishmania,
neutralization of the capacity of IL-4 to deactivate macrophages, even in the pres-SADICK ET AL .
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ence of IFN--y (37, 38), may be an important mechanism underlying the efficacy
of anti-IL-4 therapy.
Prior studies ofhealer C57BL/6 or GK1.5-BALB/cmice established acorrelation
between production of IFN-y in response to Leishmania antigen stimulation in vitro
(1) and the presence of IFN-y mRNA in lymph node and spleen cells in vivo (2)
with resolution of infection. The identification of IFN-y as a major macrophage-
activating factor andthe requirement for macrophage activation to kill this intracel-
lular parasite have been well established (5, 7, 30, 39). The studies reported here
demonstrate that IFN-y is required for healing in these mice, since the administra-
tion ofneutralizing anti-IFN-y antibody resulted in progressive, uncontrolled infec-
tion both in C57BL/6- and anti-CD4-pretreated BALB/c mice. Similarfindings have
been reported recently in studies ofL. major infection in C3H/HeN mice (40). De-
spite the requirement for IFN-y in resolution of disease in these mice, rIFN-y did
not protect BALB/c mice by itself. It did notenhance the therapeutic effects of anti-
IL-4 either, suggesting that whileimportant to the outcome of disease, IFN-y is not
sufficient by itself for the resolution of leishmaniasis in BALB/c mice.
Importantly, cure mediated by neutralization of IL-4 appeared independent of
IFN-y, since cotreatment of these mice with neutralizing anti-IFN-y mAb did not
abrogate thetherapeutic effect oftheanti-IL-4. Treatment with anti-IL-4established
protective cellular immunity, as assessed by cell transfer experiments, that resided
in both the CD4+ and CD8+ populations. Although CD4 depletion was slightly
more effective than CD8 depletion in reversing the attenuation of footpad swelling,
the CD8 requirement supports recent observations establishing aprotective role for
these cellsin leishmaniasis (41, 42). Thepossibility that macrophage-activatingfactors
other than IFN-y (43, 44) or contact-mediated macrophage activation (45, 46) are
involved in the mechanismunderlying thepotent effects ofanti-IL-4 therapyof leish-
maniasis remains to be established. The elucidation ofthemechanisms involved should
uncover novel redundant systems for the control of intracellular pathogens.
Summary
BALB/c mice infected with Leishmania majordevelop fatal, progressive disease, de-
spite an immune response characterized by expansion of CD4+ T cells in the
draining lymph nodes. The immune response has been further characterized by a
lack ofIFN-y mRNA, but increased IL-4 mRNA in lymphoid tissues, and striking
elevation of serum IgE. Treatment of infected BALB/c mice with rIFN-y at doses
shown to be beneficial in other protozoan infections was insufficient to ameliorate
L. majorinfection. In contrast, neutralization ofIL-4 by six weekly injections ofmAb
111311 led to attenuation of disease in 100% of animals, and complete cure in 85%.
Resolution ofdisease required the presence ofT cells, and recovered mice remained
resistant to reinfection at 12 wk. This immunity was adoptively transferable and
was dependent on both CD4' and CD8+ cells. Although administration of anti-IL-4
was associated with fourfold increase in IFN-ymRNA in lymph node cells draining
the lesion, the coadministration of neutralizing R4 6A2 anti-IFN-y mAb had no
effect on resistance to disease. This was in marked contrast to resolution of disease
in both resistant C57BL/6- and GK1.5-pretreated BALB/c mice that was abrogated
by in vivo treatment with anti-IFN-y. These data suggest anovel mechanism of cel-lular immunity established by interference with the development ofTh2 cells during
infection .
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